Related by context. All words. (Click for frequent words.) 74 LOMUCIN TM 69 EVIZON TM squalamine lactate 69 Qnexa TM 65 oncolytic virus therapies 64 JZP 64 EVIZON TM 64 ALN PCS 63 GVAX R 63 apricitabine ATC 63 vaginally administered lidocaine 63 SinuNase ™ 63 receptor inhibiting monoclonal 63 recombinant biopharmaceutical 63 PLK1 SNALP 62 Empatic TM 62 anti botulism antibody 62 lintuzumab SGN 62 QNEXA ® 62 neuropathic pain metabolic diseases 62 agonistic human 61 Selective Electrochemical Tumor Ablation 61 MKC# MT 61 5 HT2C serotonin 61 PSN# [002] 61 ApoB SNALP 61 Panzem R 61 XOMA 3AB 61 Nasdaq MITI biopharmaceutical 61 delta gamma agonist 60 POSIDUR TM ELADUR TM 60 GLOBE NEWSWIRE Cyclacel Pharmaceuticals 60 synthetic retinoid 60 CB2 selective receptor agonist 60 Neo Kidney Augment ™ 60 See BioWorld Today 60 PNP inhibitor 60 FOLOTYN ® 60 AAG geldanamycin analog 60 candidate XP# 60 novel VDA molecule 60 humanized interleukin 6 60 cardiovascular metabolic 60 Protexia ® 60 Shigamabs ® 60 Phase #b/#a clinical 60 PREOS R 60 candidate REP# 60 MT#/MEDI-# 60 GVAX ® 59 oral prodrug 59 non nucleoside HCV 59 sodium thiosulfate STS 59 Begins Dosing 59 NYSE Amex NBY clinical 59 glucokinase activator 59 TKM ApoB 59 including eniluracil ADH 59 Prochieve R 59 Solazed TM 59 NEBIDO R 59 Intravenous CP 59 Empatic ™ 59 gastro intestinal inflammation 59 Neo Kidney Augment 59 Phase 2a clinical trials 59 forodesine 59 MEK inhibitor 59 ALN TTR 59 THR beta agonist 59 Xyfid TM 59 products MKC# PP 59 compound COTI 59 include Inosine 59 candidate WF# 59 Prodarsan R 59 XP# XP# 59 LymphoStat B belimumab 59 targeted radiotherapeutic 59 mGluR2 NAM 59 StaphVAX R 59 investigational compounds 59 molecular imaging radiopharmaceutical 59 PDE4 inhibitor 58 non nucleoside inhibitor 58 Archexin 58 personalized cellular immunotherapy 58 SinuNase TM 58 sodium Injection 58 TBC# 58 non thiazolidinedione TZD 58 Unit Dose Budesonide 58 PANVAC VF 58 Inc. Nasdaq CYCC 58 P#X# antagonist 58 elotuzumab 58 Phase IIb trials 58 Tarmogen 58 MAXY VII 58 romazarit 58 HDL Mimetic Peptide 58 PEG irinotecan 58 Testosterone MDTS ® 58 ONCONASE R 58 investigational humanized monoclonal antibody 58 candidate CRLX# 58 adecatumumab MT# 58 negative allosteric modulator 58 telomerase therapeutic 58 R#/MEM # 58 TÎ ² 4 58 TP# CETi 1 58 ELADUR ™ 58 pralatrexate injection folate analogue 58 Completes Patient Enrollment 58 vidofludimus 58 Randomized Phase 58 therapeutic peptide 58 lomitapide 58 NYSE Amex PTN 58 includes investigational compounds 58 Phase 2a clinical 58 Veronate 57 diarrhea predominant irritable 57 MT# MEDI 57 nucleotide analog 57 Elagolix 57 Cintredekin Besudotox 57 acyclovir Lauriad R 57 Surfaxin LS 57 QNEXA 57 Inovio clinical 57 XL# anticancer compounds 57 treat opioid induced 57 Silenor ® doxepin 57 MKC# MKC# PP 57 product platforms AZX# 57 Panzem ® 57 MKC# 57 Diamyd ® 57 Genasense R oblimersen 57 novel immunotherapies 57 HCD# [002] 57 Successfully Completes Phase 57 TELINTRA R 57 next generation URAT1 57 Nasdaq MBRX announced 57 AFREZZA ® 57 Acetavance TM intravenous acetaminophen 57 novel histone deacetylase 57 OMNARIS HFA 57 hypoxia activated prodrug 57 Initiate Phase 57 PRNewswire FirstCall Genta Incorporated 57 DPP4 inhibitor 57 tiapamil 57 REMOXY R 57 ALTROPANE R 57 Inc. Nasdaq VVUS 57 PI3K/Akt pathway inhibitor 57 Allovectin 7 R 57 Hematide ™ peginesatide 57 reversible inhibitor 57 CD# CEA 57 trastuzumab DM1 T DM1 57 delta opioid receptor 57 TNFerade TM 57 Pivotal Phase 57 highly selective inhibitor 57 Janus kinase 57 MOR# 57 Telik logo TELINTRA 57 DOS# 57 Inotek Pharmaceuticals Corporation 57 albiglutide 57 Curaxin CBLC# 57 Nanobody 57 intranasal insulin product 57 Vascular Endothelial Growth 57 delivery polymer matrix 57 ARRY # 57 treat lupus renal 57 inhibit oxidative stress 57 Genasense ® oblimersen 57 Nasdaq IDRA 57 TELINTRA 57 selective immunoproteasome inhibitor 57 TRANSDUR ™ 57 2A receptor agonist 57 myasthenia gravis Huntington 57 metabotropic glutamate receptor 57 purinergic receptors P#X# 57 Zenvia ™ 57 TLR9 agonist 57 PrevOnco ™ 57 initiated Phase Ib 57 kidney urologic 56 seliciclib CYC# 56 Staphylococcus aureus Polysaccharide Conjugate 56 Onalta ™ 56 Genasense oblimersen sodium Injection 56 Phase 2a Clinical Trial 56 cathepsin K inhibitor 56 prokinetic agent 56 HuLuc# 56 CDK cyclin dependent 56 NPC 1C 56 HIV maturation inhibition 56 virus HCV protease inhibitor 56 TOCOSOL Paclitaxel 56 Initiates Phase II 56 mitogen activated ERK kinase 56 5 HT6 56 acetonide FA 56 Solazed 56 candidate NGX 56 HuMax TAC 56 orally inhaled migraine 56 Aerosurf 56 Ostabolin C TM 56 oral proteasome inhibitor 56 NASDAQ CXSP announced 56 psoriasis rheumatoid arthritis 56 include Altastaph TM 56 RNAi therapeutic targeting 56 anthrax monoclonal antibody 56 CINTREDEKIN BESUDOTOX 56 ZFP Therapeutics 56 alvespimycin 56 CEQ# 56 HCV polymerase 56 tramiprosate ALZHEMED TM 56 CYT# potent vascular disrupting 56 proprietary MSCRAMM protein 56 tramiprosate Alzhemed TM 56 immuno inflammatory diseases 56 ALN HPN 56 sodium glucose transporter 56 TRANSDUR TM Sufentanil 56 FACTIVE R gemifloxacin 56 candidate Zenvia 56 Crofelemer budesonide foam 56 mesylate tablets 56 antibody MAb 56 Valortim TM 56 Locteron exclusively 56 mGluR2 positive 56 Silodosin 56 Personalized Immunotherapy 56 selective androgen receptor modulator 56 orally administered inhibitor 56 Corporation Nasdaq MNKD 56 Evoltra ® 56 Phase IIa clinical trials 56 Maxy G# 56 QLT# 56 Troxatyl 56 rxRNA 56 INxin TM 56 Phase 2b clinical trials 56 Nasdaq ENZN 56 AFREZZA TM 56 ASONEP TM 56 Ozarelix 56 investigational protease inhibitor 56 Immunotherapeutic 56 Initiates Clinical Trial 56 lucinactant 56 Allovectin 7 r 56 Histone Deacetylase 56 rALLy clinical trial 56 Exherin TM 56 melanocortin receptor agonists 56 candidates bavituximab 56 Hedgehog pathway inhibitor 56 visilizumab 56 Alfacell proprietary ribonuclease 56 Initiated Phase 56 isoform selective 55 Phase 2b Clinical Trial 55 NASDAQ INGN 55 non alcoholic steatohepatitis 55 Quinamed R 55 novel therapeutic antibodies 55 nicotinic alpha 7 55 sodium glucose cotransporter 55 oral nucleoside analogue 55 mGluR5 negative 55 PHX# 55 histone deacetylase 55 Cleviprex TM clevidipine 55 HGS# 55 delta isoform 55 EGS# 55 torezolid phosphate 55 ALN TTR# 55 lexidronam injection 55 midstage clinical 55 immunotherapeutic vaccine 55 PEG SN# 55 HCV polymerase inhibitors 55 candidate deforolimus 55 GATTEX ® 55 Exherin 55 ATL/TV# 55 Factor Receptor 55 opioid induced bowel dysfunction 55 IL# PE#QQR 55 small molecule Hedgehog 55 Fx #A 55 candidates Azedra TM 55 receptor inhibitor 55 XmAb ® 55 JAK1 55 Nasdaq PGNX today 55 Allovectin 7 55 please visit http:/www.vandapharma.com 55 JUVISTA R Human 55 Brussels THR 55 Adnectin 55 Phase IIb clinical trials 55 NasdaqGM NTEC today 55 ALN VSP Phase 55 oral methylnaltrexone 55 MOVIPREP R 55 inhaled liposomal ciprofloxacin 55 Hedgehog antagonist 55 HepeX B TM 55 generation URAT1 inhibitor 55 Nasdaq HALO 55 dimebon latrepirdine 55 approved incretin mimetic 55 RECOTHROM ® 55 Initiates Enrollment 55 HEPLISAV ™ 55 selective phosphodiesterase 55 IMA# 55 OTCBB PYTO 55 JAK2 inhibitor 55 Gentamicin Surgical Implant 55 NTDDS 55 Nasdaq PPHM 55 NASDAQ PGNX 55 TransVax ™ 55 vaccine GRNVAC1 55 GED aPC 55 phase IIb clinical 55 Shigatoxin producing E. coli 55 Tarsa Therapeutics 55 delivers fluocinolone acetonide FA 55 novel peptides 55 LymphoStat B TM 55 VEGFR2 inhibitor 55 eniluracil 55 OvaRex ® MAb 55 % uracil topical 55 sapacitabine CYC# 55 Phase #/#a trial 55 AEG# 55 Xcytrin R 55 incyclinide 55 therapeutic monoclonal antibodies 55 Kosan dependence 55 Nasdaq PCYC 55 protein kinase inhibitors 55 5 HT2A inverse 55 IMC #B 55 ILUVIEN ® 55 sapropterin dihydrochloride Phase 55 PROGENSA R 55 Nasdaq MBRX 55 Phase IIIb clinical 55 HDAC Inhibitor 55 Aganocide ® 55 R PEG uricase 55 Kamada AAT 55 generation purine nucleoside 55 anticancer compound 55 refractory gout 55 proteasome inhibitor 55 highly purified pasteurized 55 gastrin analogue TT 54 DGAT 54 Phase III Pivotal 54 HCV NS5B polymerase 54 mda 7 54 Triolex 54 TRACON Pharmaceuticals Inc. 54 JAK inhibitor 54 Reports Preclinical Data 54 TKB# 54 REMOXY ® 54 volociximab 54 nasal calcitonin product 54 small molecule thrombopoietin 54 VSL # 54 VitiGam 54 Lenocta TM 54 VentiRx Pharmaceuticals 54 Ceragenin ™ 54 sorafenib tablets 54 YONDELIS 54 midstage trials 54 evaluating satraplatin 54 Friedreich Ataxia FRDA 54 product candidate Lpathomab 54 investigational hepatitis B 54 JOULFERON 54 deforolimus 54 Omigard 54 IAP inhibitor 54 skeletal sarcomere activators 54 immunosuppressive compound 54 Oral NKTR 54 M# rationally 54 2 methoxyestradiol 54 Hepatitis C HCV 54 CRINONE R 54 Pharmos proprietary 54 pharmacological chaperone 54 OTCQX QRXPY 54 Inc. Nasdaq MITI 54 HIV integrase inhibitor 54 candidate TNFerade biologic 54 Squalamine 54 MCSP respectively 54 IND submission 54 phase IIb study 54 TRIOLEX HE# APOPTONE HE# 54 anti CTLA 54 PEGylated interferon 54 MelaFind R 54 MyVax R 54 non porcine pancreatic 54 Shigamabs R 54 Phase 2a Trial 54 RELOVAIR ™ 54 methylnaltrexone bromide 54 TYZEKA 54 Phase IIa trials 54 CCR9 antagonist 54 ITAX 54 serine protease inhibitor CU# 54 topical anti infective 54 Inc. AMEX YMI 54 Bicifadine 54 investigational atypical antipsychotic 54 GPR# agonist 54 R sorafenib tablets 54 Factor VIIa 54 Aganocide 54 SGLT2 inhibitor 54 systemic RNAi 54 BLA filing 54 Nexavar sorafenib 54 S OMX GEN 54 HepDirect R 54 histone deacetylase HDAC 54 Nasdaq VICL 54 SomatoKine 54 anti CD3 monoclonal 54 proprietary capillary aerosolization 54 Phase Ib II 54 accumulate preferentially 54 agonist compounds 54 E1 INT TM 54 HCV RNA polymerase 54 ELACYT 54 Potelligent Technology 54 compound INCB# 54 IAP inhibitors 54 2 inhibitor CYT# 54 Angiocept 54 Nasdaq DVAX 54 Locteron ® 54 Micromet proprietary BiTE 54 Inc. NASDAQ ANPI 54 ospemifene 54 initiate multicenter 54 Civacir 54 CCR5 mAb 54 VQD 54 Darapladib 54 Rigel R# 54 Talabostat 54 Initiates Phase 54 CORT # 54 Phase 2b Trial 54 CNS Disorders 54 novel peptide 54 HCV protease inhibitor 54 IV APAP 54 LibiGel ® 54 Bioaccelerate compounds under 54 epothilone 54 antisense drug 54 Submits Biologics License Application 54 include Phenoptin TM 54 LHRH antagonist 54 teduglutide 54 inhaled formulation 54 Cyclooxygenase Inhibiting Nitric Oxide 54 therapeutic monoclonal antibody 54 Inc. Nasdaq RDEA 54 Prodarsan ® 54 Prednisporin 54 PROSTASCINT R 54 SCIB1 54 topical antifungal product 54 PAION AG ISIN 54 AFRESA ® 54 Initiates Clinical 54 RNA interference RNAi therapeutics 54 DDP# 54 CVBT #B 54 Anturol TM 53 Sphingomab TM 53 triggers apoptosis programmed 53 TLR9 agonist IMO 53 multicenter Phase III 53 TKM PLK1 53 leading oral taxane 53 EndoTAG TM -1 53 polyunsat 53 Omacetaxine 53 Ceflatonin R 53 receptor tyrosine kinase inhibitor 53 Drug Eluting Stent System 53 R roscovitine 53 Loramyc TM 53 Initiates Phase III 53 APEX PD 53 GALNS 53 OMP #R# 53 HGS ETR2 53 PRTX 53 Vegenics 53 valent pneumococcal conjugate vaccine 53 Phase 2a trial 53 Ketotransdel 53 male hypogonadism PRO 53 HEPLISAV TM 53 SPRYCEL ® 53 RECALL VAX vaccine 53 Vicriviroc 53 Entereg TM 53 Spiegelmer ® 53 CholeraGarde R Peru 53 platform HDL Mimetic 53 OTCBB HXBM developer 53 Acetavance TM 53 Alzhemed TM 53 Receives Orphan Drug Designation 53 ALS #-# 53 drug conjugate 53 NASDAQ OSIR 53 enhance ApoA 53 overactive bladder AA# 53 KNS # 53 RhuDex ® 53 pan histone deacetylase 53 BEMA Granisetron 53 GLP1 INT TM 53 registrational trial 53 5 HT2A serotonin 53 Solzira TM 53 SmartChip TM 53 preclinical toxicology 53 siRNA therapeutic 53 rALLy 53 Achieves Primary Endpoint 53 ATryn ® 53 molecular chaperone regulation 53 initiate Phase IIb 53 liposomal formulation 53 INTEGRILIN R eptifibatide Injection 53 faropenem medoxomil 53 SparVax ™ 53 Fortical ® 53 refractory chronic lymphocytic 53 Phase Ib clinical trials 53 Anturol ® 53 Intravenous Human 53 Rotarix ® 53 mertansine 53 MoneyTV Week 53 candidate Puricase 53 Enkephalin 53 reslizumab 53 IMiDs ® 53 multicenter Phase 53 Augment ™ 53 AdhTAP 53 PEGylated Fab fragment 53 AERx ® 53 cyclophilin inhibitors 53 glycogen synthase kinase 53 oral PTH 53 Cannabinor 53 histamine dihydrochloride 53 developing Surfactant Replacement 53 menopause contraception 53 phase IIa clinical 53 compound PMX # 53 JAK2 Inhibitor 53 Saxagliptin 53 Tesetaxel 53 cytokines IL 53 Nexavar ® 53 oral JAK1 53 HQK 53 SUCCEED trial 53 Iluvien ® 53 motexafin gadolinium Injection 53 Ecallantide 53 Nasdaq VRTX 53 factor VIIa 53 Presents Preclinical 53 attach auristatin 53 Modrenal R 53 recombinant Factor VIIa 53 partial agonist 53 liprotamase 53 TFChem licenses 53 phase IIa 53 Pivotal Phase III 53 MByrd Texas 53 INCB# [001] 53 PDE# 53 perifosine KRX 53 QUADRAMET R 53 metaglidasen 53 Behcet uveitis 53 humanized anti 53 neuropathic pain spasticity 53 IMPDH inhibitor 53 CholeraGarde R 53 Cloretazine ® 53 Submits Response 53 TACI Ig 53 generation calcineurin inhibitor 53 registrational 53 5 lipoxygenase inhibitor 53 protein tyrosine phosphatase 1B 53 triciribine phosphate monohydrate 53 sphingosine kinase 53 peptibody 53 ALVESCO R 53 TRIPLES Crawford Tampa Bay 53 Inc. Nasdaq MAXY 53 Zorbtive TM 53 Phase IIb Trial 53 Phase Ib clinical 53 PORxin TM 53 Alequel TM 53 lead molecular radiotherapeutic 53 PF # [002] 53 NEUGENE R 53 CD4 monoclonal antibody 53 highly selective endothelin 53 Nasdaq VNDA 53 RANK Ligand inhibitor 53 samarium Sm 53 PRX # 53 ZaBeCor 53 nitric oxide donating prostaglandin 53 Delta opioid receptor 53 preclinical 53 PRNewswire FirstCall OncoGenex Pharmaceuticals 53 TRAIL receptor 53 LUNESTA TM 53 cutaneous T 53 ELND-#/AZD-# 53 using VIAdel TM 53 Initiates Phase 2b 53 monounsat 53 Augment TM 53 Meets Primary Endpoint 53 Chris McKhann March 53 pulmonology portfolio 53 Cloretazine R 53 AcryMed Incorporated 53 Files IND 53 Receives Milestone Payment 53 SGLT2 53 Zybrestat 53 Somatuline Depot 53 Nanobody R 53 Dyloject TM 53 intranasal formulation 53 proprietary BiTE ® 53 catheter occlusion 53 Nasdaq ACHN 52 BiTE antibody 52 AKT inhibitor 52 Onalta 52 Aflibercept 52 ChronVac C R 52 Shigamabs 52 antigen rPA anthrax 52 radiation sensitizer 52 myelofibrosis polycythemia vera 52 tafamidis 52 Fibrillex TM 52 novel orally administered 52 THALOMID 52 dirucotide 52 Phase 1a clinical 52 IIb clinical trial 52 CRD5 52 placebo controlled Phase 52 Versartis 52 cosmetic cosmeceutical products 52 EVIZON ™ 52 Guanilib 52 NICOSAN ™ 52 Sudhir Agrawal D.Phil 52 ATHX 52 TKM Ebola 52 Oracea TM 52 NPSP# 52 Qutenza TM 52 Tesmilifene 52 sterile lidocaine patch 52 Submits NDA 52 Protease Inhibitor 52 castrate resistant prostate cancer 52 severe gastroparesis 52 RSD# oral 52 PDX pralatrexate 52 bardoxolone 52 dasatinib Sprycel ® 52 platinum chemotherapeutic 52 agent bevasiranib 52 TRAIL Receptor 52 miconazole Lauriad 52 vilazodone 52 RNAi Therapeutic 52 histone deacetylase HDAC inhibitor 52 Synagis palivizumab 52 Phase IIb Clinical Trial 52 HCV polymerase inhibitor 52 AFREZZA ™ 52 Rhucin ® recombinant 52 HTS assay 52 selective modulator 52 Gonal f R 52 MOZOBIL 52 inflammatory PDE 52 VEGF Trap 52 Abiraterone acetate 52 SparVax TM 52 DRoberts San Diego 52 NDA Submission 52 AdVac R 52 NU# direct 52 Pruvel 52 Present Preclinical Data 52 Corlux 52 receptor agonist 52 Tezampanel 52 Nasdaq IDRA today 52 Actemra tocilizumab 52 drug GAP #B# 52 exon skipping 52 CGuzman Minnesota 52 EOquin TM phase 52 receptor partial agonist 52 antibody fragment therapeutics 52 infectious diseases autoimmune diseases 52 TBC M4 52 Peyronie disease Frozen Shoulder 52 commercialize ZYFLO CR 52 proprietary bioresorbable polymer 52 methionine aminopeptidase 52 Zalypsis 52 microsomal triglyceride transfer 52 Safinamide 52 MTP inhibitor 52 lenalidomide Revlimid R 52 systemic juvenile idiopathic 52 includes TOLAMBA TM 52 paclitaxel Taxol ® 52 post herpetic neuralgia PHN 52 SUVN 52 Commences Phase 52 humanized therapeutic 52 Ophena TM 52 oxybutynin ATD TM 52 PROVENGE sipuleucel T 52 methylnaltrexone 52 Staccato loxapine 52 Biologic License Application BLA 52 ASONEP ™ 52 PGL# 52 Phase lll 52 Pruvel TM 52 VALSTAR R 52 IND enabling 52 Therapeutic Competitors Companies 52 Urocidin TM 52 panose 1 52 XOMA 3AB biodefense 52 EndoTAG TM 52 hoFH 52 immune modulator 52 Familial Adenomatous Polyposis FAP 52 Valtropin 52 Phase III Clinical Trial 52 RenaZorb TM 52 e# DOI #.#/journal.pone.# 52 Dacogen injection 52 postherpetic neuralgia PHN 52 Tyrosine Kinase Inhibitor 52 blinded randomized placebo controlled 52 INCH RANGE 52 CRMD# 52 Icatibant 52 APF# 52 Muraglitazar 52 FDA APPROVES 52 infectious diseases autoimmune 52 commercialize CorMedix drug 52 By KBJR News 52 Prodarsan 52 rufinamide 52 Inc. Nasdaq IDMI 52 aurora kinase 52 Nicky Hayden Honda +#.# 52 IMiDs R 52 investigational hepatitis C 52 anthrax botulism tuberculosis typhoid 52 staphylococcal vaccines 52 candidate brentuximab vedotin 52 Thelin tm 52 maribavir 52 NASDAQ IDEV 52 Dose Escalation 52 Phase 2b clinical 52 TAXUS Element Stent System 52 receptor modulators 52 patented DepoVax TM 52 rusalatide acetate 52 recombinant protective 52 Cx# [002] 52 use neuroblocking technology 52 AERx iDMS 52 Daclizumab 52 EHT AGN 52 opioid bowel dysfunction 52 introduced NEUGENE 52 AQ4N 52 phase IIb 52 Flutiform ™ 52 recombinant influenza 52 Diabetic Macular Edema DME 51 Pharmion Corporation 51 POLITICS IN BRIEF 51 Morning Communiqué 51 methyl CpG binding 51 Drug Candidate 51 Pharmos pipeline 51 Anturol 51 small molecule tyrosine 51 dextromethorphan quinidine 51 predictive toxicology 51 OraTest R 51 Lixivaptan 51 Topical Interferon Alpha 2b 51 HepeX B 51 MORAb 51 Homspera TM 51 Phase IIB 51 dacetuzumab SGN 51 IgG1 monoclonal antibody 51 Phenoptin 51 TRO# 51 application sNDA 51 5 HT6 receptor 51 IMiD 51 CGuillen Detroit 51 Adenosine Therapeutics 51 ATryn R 51 ABthrax TM raxibacumab 51 PREVENAR 51 ocular formulation 51 Evoltra R 51 Octreotide 51 OXIGON 51 commercializing oxidized glutathione 51 Pharma Merck Serono 51 RNAi therapeutic 51 Urocidin 51 PHARMACEUTICALS INC 51 Phase #b/#a trial 51 proprietary Capillary Aerosolization Technology 51 Valley Fri 6a 51 HCV protease inhibitors 51 CYT# vascular disrupting 51 NS5b 51 topically applied SEPA 51 TLR9 agonists 51 sumatriptan DosePro 51 EGFR HER2 51 Degarelix 51 drug GLPG# 51 polysaccharide polymer 51 Bremelanotide 51 drug ISA# 51 VALSTAR 51 lead Aganocide compound 51 MAGE A3 ASCI 51 thrombopoietin TPO 51 phase Ib clinical 51 Nasdaq OSCI 51 Oncaspar 51 Plasma Converter TM 51 rhMBL 51 SAR# [002] 51 Stocks Approaching Greatness 51 humanized monoclonal antibody 51 transmucosal delivery 51 Premarket Approval Application 51 Aryplase 51 THIS DEAL ENDS 51 allosteric modulator PAM 51 PrevOnco 51 pathophysiological effects 51 cholesteryl ester transfer 51 Protexia R 51 A3 adenosine receptor 51 ® bortezomib 51 Albuferon albinterferon alfa 2b 51 Memryte 51 Thalomid ® 51 Junovan TM 51 Golimumab 51 Aviptadil 51 Tarceva TM 51 drug conjugates ADCs 51 ERYtech 51 Onconase 51 demonstrated antitumor activity 51 SFinley San Francisco 51 immunotoxin 51 equine osteoarthritis marketed 51 antibody MT# 51 humanized monoclonal 51 Recombinant Human 51 dependent cellular cytotoxicity 51 REGENERX BIOPHARMACEUTICALS INC. 51 SonoLysis 51 memantine HCl 51 Lenocta 51 Cerashield ™ 51 CD# monoclonal antibody 51 cetuximab Erbitux R 51 allosteric modulator NAM 51 Decitabine 51 MEK inhibitor RDEA# 51 pm Bugz Casino 51 octreotide implant 51 Locked Nucleic Acid 51 ZALBIN 51 secretory phospholipase A2 51 Raptiva ® 51 OncoVex 51 Onco TCS 51 candidate FAV 51 Stimuvax R 51 Thiarabine 51 HyperAcute 51 NASDAQ ARRY 51 Flutiform TM 51 alpha folate receptor 51 humanized monoclonal antibodies 51 BRAF kinase 51 Janus Kinase 51 Like Receptor 51 Receptor TLR 51 cinacalcet HCl 51 sarcoma melanoma 51 zolpidem tartrate sublingual tablet 51 Alvesco R 51 polymerase inhibitor 51 Mullah Adahdad killed 51 Prednisporin TM 51 targeted antifolate 51 imatinib Gleevec ® 51 selective A2A adenosine receptor 51 Immunomedics Announces 51 confirmatory Phase III 51 NovaDel oral spray 51 Luveniq 51 oncolytic virus therapy 51 ADP receptor antagonist 51 Biomoda www.biomoda.com 51 alpha 2A adrenergic 51 oral ridaforolimus 51 blockers angiogenesis inhibitors